Navigation Links
Study Published in Molecular Therapy Shows that Immune Response to FANG™ Personalized Cancer Therapeutic Correlates with Prolonged Survival in Patients with Advanced Stage Cancer
Date:3/1/2012

DALLAS, March 1, 2012 /PRNewswire/ -- Today Gradalis, Inc., announced that FANG™, the company's tumor-based personalized cancer therapeutic, elicits a robust and lasting immune response, resulting in statistically-significant prolonged survival in patients with advanced stage disease. The Phase 1 study, published today in the Nature Publishing Group journal Molecular Therapy, showed that treatment with FANG significantly increased survival in patients with advanced stage cancer compared to patients who received other forms of treatment in this non-randomized study.

The study evaluated 46 patients with varying tumor types, including melanoma, colorectal, breast, ovarian and hepatocellular cancers. A personalized FANG vaccine was manufactured from tumors removed from 42 of the 46 patients, and 27 patients received one monthly dose of the vaccine for up to 12 months. Twenty-three of the 27 patients receiving FANG achieved stable disease within two months of dose initiation. Median survival for the FANG group was 554 days compared to 132 days for the group that did not receive FANG. (P<0.0001) The "no FANG" group included 18 patients who had vaccine made but did not receive injections due to progression of disease or pursuit of other treatment options. FANG was well tolerated by all patients, and there were no treatment-related serious adverse events.

"The pronounced survival benefit achieved by FANG in patients with multiple tumor types is quite remarkable, and randomized Phase 2 trials are currently underway verifying these results," said John Nemunaitis, M.D., executive medical director of the Mary Crowley Cancer Research Centers and chief medical officer and co-founder of Gradalis. "The benefit is likely attributed to the triad approach which is designed into the vaccine to maximize its effect.  FANG is not only manufactured using each individuals' tumor to assure exposure to the appropriate antigens, but it also activates
'/>"/>

SOURCE Gradalis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study
2. Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups
3. Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
4. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
5. Preclinical Study Examines Use of nContacts Technology in Enabling a Percutaneous Device Approach to Epicardial Ablation
6. CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
7. Medical Device Study Examines Use of Emerging Markets and Outsourcing for Clinical Activities
8. Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
9. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
10. Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono
11. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Sanomedics International ... 2014 report by Global Research & Data Services, demand ... year from 2014 through 2018, as demand for more ... is the world,s largest market for thermometers, ... advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... and AUSTIN, Texas , ... PureMHC LLC today announced they have entered into ... antibody-based immunotherapies designed to target cancers. ... peptides displayed on the surfaces of tumor cells ... targets (PTTs), derived from proteins that play a ...
(Date:10/22/2014)... 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... IAP310 study have been published in Regional ... journal with broad, multidisciplinary readership. IAP310 was a ... and efficacy of Zalviso, also referred to as ... treatment of post-operative pain in patients following open ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
(Date:10/22/2014)... Arbor, MI (PRWEB) October 22, 2014 ... of Schools of Allied Health Professions (ASAHP) Conference on ... Founder and CEO will participate in a panel discussion ... and Practice. , Isabel Healthcare provides a diagnostic decision ... in improving the diagnosis skills of students and clinical ...
(Date:10/22/2014)... RESTON, Va. (PRWEB) October 22, 2014 ... Healthcare Innovation , which is dedicated to distribute ... efficiency of healthcare delivery worldwide announced the development ... in which patients expect when receiving healthcare. These ... definition for patient-centered care: “providing care that is ...
(Date:10/22/2014)... Texas (PRWEB) October 22, 2014 ... of completing their continuing education at home or ... have access to 20 brand new, premium Seminar-on-Demand ... robust catalog of over 2,000 hours ... fully customize their educational experience. With such a ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Akeso ... solutions for the treatment of bacterial infections, microbial biofilms, ... has joined its board of directors. , ... Engineering Systems at The Massachusetts Institute of Technology, or ... faculty since 1968. Dr. Sinskey also holds positions as ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... have found an explanation for runners who struggle to increase ... who cant speed up their strokes. Researchers from the University ... changes that occur in our muscles when we push ourselves ... of exercise intensity, known as the critical power. This level ...
... CHARLOTTE, N.C., Dec. 20 MedCath Corporation,(Nasdaq: MDTH ... as,Executive Vice President and Chief Financial Officer to become ... Co.,Consolidated, a company with whom he has several years, ... Committee since 2003. Harris,who will remain with MedCath until ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... will be held January 7-10, 2008 at the Westin,St. ... ), Robert Holster, Chairman and CEO of HMS ... p.m. Pacific Time., A live broadcast of the ...
... to Discuss Latest Criminal,Cases, Decrees and How They Now ... 20 In the last year,mainstream drug and device ... fines, civil settlements and penalties. Top drug company,executives have ... in or know about the crimes., With the ...
... Agri-Opportunities program of Agriculture and ... ... Bioniche Life Sciences,Inc. (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, ... financing in support of its vaccine production,facility scale-up in Belleville, ...
... December 20, 2007 For U.S. veterans with diabetes, ... are associated with an increased risk of major amputations, ... journal General Hospital Psychiatry. , "Our findings suggest that ... health functioning as a risk factor and to develop ...
Cached Medicine News:Health News:Why exertion leads to exhaustion 2Health News:James E. Harris to Become Chief Financial Officer of Coca-Cola Bottling Co. Consolidated 2Health News:Food and Drug Law Institute Sponsors Major Enforcement Conference 2Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 2Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 3Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 4Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 5Health News:Mental health linked to amputation risk in diabetic veterans 2
... The Autocorr Pulse Oximeter with SAC (Serial ... patented software to extract SpO 2 , ... a new way. This cost-effective compact ... functions as standard features, and a data ...
... The Autocorr Plus, the fourth in ... versatile pulse oximeter/ECG/Respiration Monitor, with 3 ... digital oximetry with SAC (Serial Autocorrelation) ... electroluminescent screen display provides two user ...
... Oximeter is a cost-effective, stand-alone monitor that ... rate and pulse strength measurements of patients ... or battery powered unit displays a plethysmographic ... up to 30 hours of on screen ...
... is a second-generation refractive multifocal IOL that ... from glasses than monofocal IOLs. The ReZoom ... vision that monfocals cannot match. , ,The ... over five optic zones so that each ...
Medicine Products: